Denileukin diftitox

Denileukin diftitox
Clinical data
Trade namesOntak, others
AHFS/Drugs.comMonograph
MedlinePlusa611024
License data
Routes of
administration
Intravenous
Drug classAntineoplastic
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life70-80 min
Identifiers
  • Diphtheria toxin-Interleukin-2 fusion protein
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC2560H4042N678O799S17
Molar mass57647.46 g·mol−1
 X markNcheckY (what is this?)  (verify)
Denileukin diftitox-cxdl
Clinical data
PronunciationDEH-nih-LOO-kin DIF-tih-tox
Trade namesLYMPHIR
Other namesE7777; formerly I/ONTAK; DAB389IL-2 (historical)
AHFS/Drugs.commonograph
MedlinePlusa611024
License data
Pregnancy
category
  • Can cause fetal harm
Routes of
administration
Intravenous infusion
Drug classIL-2 receptor-directed cytotoxin; antineoplastic immunotoxin
ATC code
Legal status
Legal status
  • US: ℞-only
  • FDA-approved 7 August 2024; orphan drug for CTCL and PTCL
Pharmacokinetic data
Bioavailability100% by intravenous administration
Protein bindingNot formally characterized
MetabolismProteolytic degradation
Elimination half-lifeApproximately 112 minutes, cycle 1 terminal
ExcretionProteolytic degradation
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
Chemical and physical data
Molar mass58 kDa recombinant fusion protein

Denileukin diftitox, sold under the brand name Ontak from 1999-2014, was an anti-cancer medication approved for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.

Denileukin diftitox-cxdl, sold under the brand name LYMPHIR, is an interleukin-2 (IL-2) receptor–directed cytotoxin (immunotoxin) used to treat cutaneous T-cell lymphoma (CTCL). It is a recombinant fusion protein that combines an IL-2 ligand with a fragment of diphtheria toxin.

In 2024, the U.S. Food and Drug Administration (FDA) approved denileukin diftitox-cxdl in the United States. for the treatment of adults with relapsed or refractory stage I–III CTCL after at least one prior systemic therapy. Denileukin diftitox-cxdl is administered by intravenous infusion.

A prior formulation of denileukin diftitox (marketed as Ontak) was approved in 1999 and was voluntarily withdrawn from the U.S. market in 2014. In 2021, the current more bioactive formulation was also approved in Japan.